[26.02.2012] - ImmunNovative Development, two years of business history
ImmunNovative Developments (IND) — specializing in the development of new biological drugs to prevent, diagnose and treat multi-resistant infections and other immune-based inflammatory diseases, has completed its second year of business this February. Despite its short business life, this biotech company- based at the Bioincubator at the Barcelona Science Park (PCB) -is about to finalize the preclinical phase of two broad-spectrum first-in-class antisepsis products and has been selected as one of the 4 best European biotech life sciences company by the European Venture Contest 2011. IND´s past work has also been recognized by other important national and international awards: in 2010 IND was finalist of the BioEntrepeneur XX in 2010 and in 2011 it was semifinalist of the 5th edition of the European Venture Summit 2011.Read more...
[19.12.2011] - ImmunNovative, the best 4th biotech company in Europe
ImmunNovative Developments (IND) has been considered as one of the best 4 biotech companies in the category of Life Sciences among 800 European institutions from different 17 countries, according to the Civica European Venture Contest (CEVC) held on 14 December in Madrid.
[28.11.2011] - ImmunNovative Developments, finalist in the 5th edition of the European Venture Summit
The biotech Immunovative Developments, based at the Barcelona Science Park, is a finalist in the 5th edition of the European Venture Summit, which took place on November 28 and 29 in the German city of Doüseldorf. The 150 companies that won the competitions held in Europe, in which a total of 800 companies participated, took part in this summit in order to showcase their businesses to international investors and other industry experts. Following this semi-final, Immunovative will compete with the 24 finalist companies, 7 of which are also biotechs, in Madrid.Read more...
[09.11.2011] - Presubmission Meeting @ EMA
IND attended the "presubmission meeting" held at the European Medicines Agency (EMA) on 9 November, as part of the Scientific Advice process, a step that is being carried out in order to validate a regulatory strategy and development plan for IND-006.